Please login to the form below

Not currently logged in
Email:
Password:

RSV trial

This page shows the latest RSV trial news and features for those working in and with pharma, biotech and healthcare.

AZ, Sanofi’s nirsevimab hits primary endpoint in RSV trial

AZ, Sanofi’s nirsevimab hits primary endpoint in RSV trial

AstraZeneca (AZ) and Sanofi’s long-acting antibody nirsevimab met the primary endpoint in a late-stage respiratory syncytial virus (RSV) trial in healthy infants. ... According to the companies, nirsevimab is the first potential immunisation to show

Latest news

  • GSK launches late-stage testing of RSV vaccine candidate in older adults GSK launches late-stage testing of RSV vaccine candidate in older adults

    GlaxoSmithKline (GSK) has launched a phase 3 trial investigating its respiratory syncytial virus (RSV) vaccine candidate in older adults. ... In a phase 1/2 trial of GSK’s RSV vaccine candidate in both young and older adults, the jab was found to have

  • Novacyt launches diagnostic test to differentiate between COVID-19 and flu Novacyt launches diagnostic test to differentiate between COVID-19 and flu

    RSV). According to the company, clinical trial data of the test demonstrated 100% specificity and between 96% and 100% sensitivity across the panel.

  • Regeneron and Bayer drop AMD combination Regeneron and Bayer drop AMD combination

    Abandon plans after disappointing phase II trial results. Regeneron has abandoned a combination therapy for age-related macular degeneration after disappointing phase II data, handing an advantage to would-be rival ... This is the second pipeline

  • Gilead's RSV drug clears mid-stage trial Gilead's RSV drug clears mid-stage trial

    Other companies developing therapeutics for RSV include ADMA Biologics, which recently completed enrolment in a phase III trial of its RI-002 immunoglobulin candidate, Teva's MicroDoseTherapeutx, whose inhalable fusion inhibitor ... MDT-637 recently

  • Flicking the switch

    RSV infections can lead to serious respiratory conditions such as croup, pneumonia and bronchiolitis. ... In April 2008, Alnylam went on to initiate a phase II trial of ALN-RSV01 in adult lung transplant patients naturally infected with RSV.

More from news
Approximately 0 fully matching, plus 7 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
integrated medhealth communication

imc group is a leading, independent global healthcare communication group that enables client’s brands to connect with healthcare professionals, payers...

Latest intelligence

Diversity in clinical trials: looking back at our 2021 blogs
In this blog, we look back at the Innovative Trials' Equality & Diversity (E&D) committee blogs across 2021...
What does the future hold for Light-chain Amyloidosis?
Recent advances in the understanding and treatment are reforming pharma’s approach to the management of this rare disease. With a new standard of care rapidly developing, what does the landscape...
Webinar:
Securing a future for telehealth with immersive market research insights...